BANGLADESH overcame stiff resistance from Zimbabwe batsmen to win a one-off Test by 220 runs at Harare Sports Club on Sunday (11).
Needing 477 to win, the hosts were all out for 256 after brave innings from nightwatchman Donald Tiripano and fast-medium bowler Blessing Muzarabani delayed the tourists' celebrations.
It was the fifth Test victory for Bangladesh outside the country and a fitting send-off for all-rounder Mahmudullah Riyad, who is retiring from the longest format after an unbeaten career-best 150, his fifth Test century, in the first innings.
The visitors formed a guard of honour for Mahmudullah, playing his 50th Test since making his debut in 2009, and let him lead the team on to the pitch for the final day, which began with Zimbabwe 140-3.
New cap Dion Myers added a further 19 in tandem with Tiripano before Bangladesh made a telling breakthrough.
Myers eked out 26 from 88 balls, a nuggety innings punctuated by two sixes and helped by two dropped chances by wicketkeeper Liton Das and Shakib al Hasan.
He was undone by off-spinner Mehidy Hasan Miraz, chipping him straight to Shadman Islam at midwicket.
The departure of Myers triggered a collapse as Zimbabwe slumped to 176-7 at lunch.
Timycen Maruma and Roy Kaia were both trapped leg before for ducks and wicketkeeper Regis Chakabva made just one before being bowled by Taskin Ahmed who finished with 4-82.
But Bangladesh's hopes of wrapping up a victory swiftly were dashed as Tiripano and Muzarabani dug in to add 41 for the ninth wicket.
Tiripano made 52 off 144 balls before edging a good-length delivery from Ebadot Hossain and a diving Das made the catch.
Muzarabani finished unbeaten on 30, having faced 51 balls in 93 minutes and struck four fours.
But Bangladesh completed the victory when Richard Ngarava went for a big slog against Mehidy and lost his middle stump.
Mehidy finished with 4-66 to give him nine wickets in the match.
The all-format tour by Bangladesh resumes on Friday (16) with the first of three one-day internationals, which will be followed by three Twenty20 internationals.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.